COMMUNIQUÉS West-GlobeNewswire

Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
04/02/2026
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a [...]
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
04/02/2026
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney [...]
Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026
04/02/2026
WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
Experience Truly Natural Results: Aesthetics International Leads the Region with Expressive Botox Expertise
04/02/2026
The Era of "Invisible" Enhancements: Aesthetics International Introduces Expressive Botox to Dubai’s Elite Wellness Scene DUBAI, United Arab Emirates, Feb. 04, 2026 (GLOBE NEWSWIRE) -- As Dubai solidifies its reputation [...]
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
04/02/2026
Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical [...]
Levicept Announces the Appointment of James Sandy as Chief Development Officer
04/02/2026
Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of [...]
Michigan Integrative Health Expands Stem Cell Therapy Services to Welcome Canadian Patients
04/02/2026
DETROIT, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Michigan Integrative Health Stem Cells , a leading provider of stem cell therapy and regenerative medicine in Shelby Township, Michigan, announces the expansion of its service [...]
Novo Nordisk initiates 2026 share repurchase programme
04/02/2026
Bagsværd, Denmark, 4 February 2026 –The execution of Novo Nordisk A/S’ overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 February 2026. As part of this, Novo Nordisk A/S today [...]
Novo Nordisk has published its annual report for 2025
04/02/2026
Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: https://www.novonordisk.com/investors/annual-report.html and is attached in iXBRL format. [...]
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury
04/02/2026
Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM ® System to address blood pressure instability after spinal cord injury (SCI) Blood pressure instability is [...]
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
04/02/2026
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today [...]
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
04/02/2026
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc 1 , +8% USD) with core operating income 1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from priority brands [...]
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
04/02/2026
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPF Findings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, [...]
Herz P1 Smart Scale: 8-Electrode Body Composition Tracking Device With 56 Metrics — Product Information Updated for 2026
04/02/2026
An informational overview examining dual-frequency BIA technology, segmental body composition analysis, no subscription fee access, and what consumers researching home wellness tracking devices consider when comparing [...]
Telix Full Year Results 2025 Investor Webcast Notification
03/02/2026
MELBOURNE, Australia and INDIANAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that it will release its full year results for the period ended 31 December [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
03/02/2026
LOUISVILLE, Ky., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its fourth quarter and full year 2025 [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]

Pages